Core Viewpoint - Weigao Co., Ltd. (01066) experienced a decline of over 5% in early trading, currently down 4.91% at HKD 5.04, with a trading volume of HKD 18.4665 million [1] Group 1: Acquisition Details - Weigao Blood Products (603014) announced on January 5 that it plans to acquire 100% equity of Weigao Purui from three parties through a share issuance, with a transaction price of approximately RMB 8.511 billion [1] - Following the completion of the transaction, Weigao Purui will become a wholly-owned subsidiary of the company, adding pharmaceutical packaging-related business to its main operations [1] Group 2: Market Position and Impact - Weigao Purui holds the largest market share in pre-filled products in China, with over 50% market share from 2022 to 2024, ranking first in the domestic market and among the top five in international sales [1] - The acquisition is expected to enhance the company's profitability and investment value by incorporating a high-quality asset with strong earnings capabilities into the consolidated financial statements of the listed company [1]
威高股份跌超5% 威高血净拟斥资85亿元向威高股份等收购威高普瑞